Is Can-Fite BioPharma Ltd. (CANF) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.7% / 30% | 132.4% / 30% | 0.0% / 30% | 43.18% / 5% | ✗ NOT HALAL |
| DJIM | 1.7% / 33% | 132.4% / 33% | 0.0% / 33% | 43.18% / 5% | ✗ NOT HALAL |
| MSCI | 1.1% / 33% | 86.5% / 33% | 0.0% / 33% | 43.18% / 5% | ✗ NOT HALAL |
| S&P | 1.7% / 33% | 132.4% / 33% | 0.0% / 33% | 43.18% / 5% | ✗ NOT HALAL |
| FTSE | 1.1% / 33% | 86.5% / 33% | 0.0% / 50% | 43.18% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -2488.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -178.2% | |
| Return on Assets (ROA) | -66.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $104,000 |
| Debt-to-Equity | 1.3 |
| Current Ratio | 3.5 |
| Total Assets | $9M |
Price & Trading
| Last Close | $3.29 |
| 50-Day MA | $4.15 |
| 200-Day MA | $10.01 |
| Avg Volume | 905K |
|
52-Week Range
$3.11
| |
About Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Can-Fite BioPharma Ltd. (CANF) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Can-Fite BioPharma Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Can-Fite BioPharma Ltd.'s debt ratio?
Can-Fite BioPharma Ltd.'s debt ratio is 1.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are Can-Fite BioPharma Ltd.'s key financial metrics?
Can-Fite BioPharma Ltd. has a market capitalization of $7M, and revenue of $674,000. Return on equity stands at -178.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.